Al-Rubaye H, Perfetti G, Kaski J-C. The role of microbiota in cardiovascular risk: focus on trimethylamine oxide. Curr Probl Cardiol. 2019;44:182–96.
Google Scholar
Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in human health. EXCLI J. 2021;20:301–19.
Google Scholar
Li D, Lu Y, Yuan S, Cai X, He Y, Chen J, et al. Gut microbiota-derived metabolite trimethylamine-N-oxide and multiple health outcomes: an umbrella review and updated meta-analysis. Am J Clin Nutr. 2022;116:230–43.
Google Scholar
Xu H, Wang X, Feng W, Liu Q, Zhou S, Liu Q, et al. The gut microbiota and its interactions with cardiovascular disease. Micriob Biotechnol. 2020;13:637–56.
Google Scholar
Gong D, Zhang L, Zhang Y, Wang F, Zhao Z, Zhou X. Gut microbial metabolite trimethylamine N-oxide is related to thrombus formation in atrial fibrillation patients. Am J Med Sci. 2019;358:422–8.
Google Scholar
Li XS, Obeid S, Klingenberg R, Gencer B, Mach F, Räber L, et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J. 2017;38:814–24.
Google Scholar
Waleed KB, Tse G, Lu Y-K, Peng C-N, Tu H, Ding L-G, et al. Trimethylamine N-oxide is associated with coronary atherosclerotic burden in non-ST-segment myocardial infarction patients: SZ-NSTEMI prospective cohort study. Rev Cardiovasc Med. 2021;22:231–8.
Google Scholar
Zhou X, Jin M, Liu L, Yu Z, Lu X, Zhang H. Trimethylamine N-oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction. ESC Heart Fail. 2020;7:188–93.
Google Scholar
Li N, Zhou J, Wang Y, Chen R, Li J, Zhao X, et al. Association between trimethylamine N-oxide and prognosis of patients with acute myocardial infarction and heart failure. ESC Heart Fail. 2022;9:3846–57.
Google Scholar
Senthong V, Wang Z, Li XS, Fan Y, Wu Y, Wilson Tang WH, et al. Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort. J Am Heart Assoc. 2016;5:e002816.
Google Scholar
Sheng Z, Tan Y, Liu C, Zhou P, Li J, Zhou J, et al. Relation of circulating trimethylamine N-oxide with coronary atherosclerotic burden in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2019;123:894–8.
Google Scholar
Tan Y, Sheng Z, Zhou P, Liu C, Zhao H, Song L, et al. Plasma trimethylamine N-oxide as a novel biomarker for plaque rupture in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2019;12:e007281.
Google Scholar
Baranyi A, Enko D, von Lewinski D, Rothenhäusler H-B, Amouzadeh-Ghadikolai O, Harpf H, et al. Assessment of trimethylamine N-oxide (TMAO) as a potential biomarker of severe stress in patients vulnerable to posttraumatic stress disorder (PTSD) after acute myocardial infarction. Eur J Psychotraumatol. 2021;12:1920201.
Google Scholar
Tang WHW, Wang Z, Shrestha K, Borowski AG, Wu Y, Troughton RW, et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail. 2015;21:91–6.
Google Scholar
Dong Z, Zheng S, Shen Z, Luo Y, Hai X. Trimethylamine N-oxide is associated with heart failure risk in patients with preserved ejection fraction. Lab Med. 2021;52:346–51.
Google Scholar
Heianza Y, Ma W, DiDonato JA, Sun Q, Rimm EB, Hu FB, et al. Long-term changes in gut microbial metabolite trimethylamine N-oxide and coronary heart disease risk. JACC. 2020;75:763–72.
Google Scholar
Almesned MA, Prins FM, Lipšic E, Connelly MA, Garcia E, Dullaart RPF, et al. Temporal course of plasma trimethylamine N-oxide (TMAO) levels in ST-elevation myocardial infarction. J Clin Med. 2021;10:5677.
Google Scholar
Matsuzawa Y, Nakahashi H, Konishi M, Sato R, Kawashima C, Kikuchi S, et al. Microbiota-derived trimethylamine N-oxide predicts cardiovascular risk after STEMI. Sci Rep. 2019;9:11647.
Google Scholar
Li N, Wang Y, Zhou J, Chen R, Li J, Zhao X, et al. Association between the changes in trimethylamine N-oxide-related metabolites and prognosis of patients with acute myocardial infarction: a prospective study. J Cardiovasc Dev Dis. 2022;9:380.
Google Scholar
Schneider C, Okun JG, Schwarz KV, Hauke J, Zorn M, Nürnberg C, et al. Trimethylamine-N-oxide is elevated in the acute phase after ischaemic stroke and decreases within the first days. Eur J Neurol. 2020;27:1596–603.
Google Scholar
Ringel C, Dittrich J, Gaudl A, Schellong P, Beuchel CF, Baber R, et al. Association of plasma trimethylamine N-oxide levels with atherosclerotic cardiovascular disease and factors of the metabolic syndrome. Atherosclerosis. 2021;335:62–7.
Google Scholar
Wang A, Li Z, Zhuo S, Gao F, Zhang H, Zhang Z, et al. Mechanisms of cardiorenal protection with SGLT2 inhibitors in patients with T2DM based on network pharmacology. Front Cardiovasc Med. 2022;9:857952.
Google Scholar
von Lewinski D, Benedikt M, Tripolt N, Wallner M, Sourij H, Kolesnik E. Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction? Kardiol Pol. 2021;79:503–9.
Wang D, Liu J, Zhou L, Zhang Q, Li M, Xiao X. Effects of oral glucose-lowering agents on gut microbiota and microbial metabolites. Front Endocrinol. 2022;13:905171.
Google Scholar
Deng L, Yang Y, Xu G. Empagliflozin ameliorates type 2 diabetes mellitus-related diabetic nephropathy via altering the gut microbiota. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867:159234.
Google Scholar
Xu M, Zheng J, Hou T, Lin H, Wang T, Wang S, et al. SGLT2 inhibition, choline metabolites, and cardiometabolic diseases: a mediation Mendelian randomization study. Diabetes Care. 2022;45:2718–28.
Google Scholar
Lee DM, Battson ML, Jarrell DK, Hou S, Ecton KE, Weir TL, et al. SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice. Cardiovasc Diabetol. 2018;17:62.
Google Scholar
Tripolt NJ, Kolesnik E, Pferschy PN, Verheyen N, Ablasser K, Sailer S, et al. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial. Am Heart J. 2020;221:39–47.
Google Scholar
von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43:4421–32.
Google Scholar
Enko D, Zelzer S, Baranyi A, Herrmann M, Meinitzer A. Determination of trimethylamine-N-oxide by a simple isocratic high-throughput liquid-chromatography tandem mass-spectrometry method. Clin Lab. 2020;66:1801–8.
Google Scholar
Suzuki T, Yazaki Y, Voors AA, Jones DJL, Chan DCS, Anker SD, et al. Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure: results from BIOSTAT-CHF. Eur J Heart Fail. 2019;21:877–86.
Google Scholar
Gessner A, di Giuseppe R, Koch M, Fromm MF, Lieb W, Maas R. Trimethylamine-N-oxide (TMAO) determined by LC-MS/MS: distribution and correlates in the population-based PopGen cohort. Clin Chem Lab Med. 2020;58:733–40.
Google Scholar
Wang Z, Levison BS, Hazen JE, Donahue L, Li X-M, Hazen SL. Measurement of trimethylamine-N-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry. Anal Biochem. 2014;455:35–40.
Google Scholar
Schiattarella GG, Sannino A, Toscano E, Giugliano G, Gargiulo G, Franzone A, et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur Heart J. 2017;38:2948–56.
Google Scholar
Heianza Y, Ma W, Manson JE, Rexrode KM, Qi L. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. J Am Heart Assoc. 2017;6:e004947.
Google Scholar
Heerspink HJL, Cherney DZI. Clinical implications of an acute dip in eGFR after SGLT2 inhibitor initiation. Clin J Am Soc Nephrol. 2021;16:1278.
Google Scholar
Missailidis C, Hällqvist J, Qureshi AR, Barany P, Heimbürger O, Lindholm B, et al. Serum trimethylamine-N-oxide is strongly related to renal function and predicts outcome in chronic kidney disease. PLoS ONE. 2016;11:e0141738.
Google Scholar
Guo F, Qiu X, Tan Z, Li Z, Ouyang D. Plasma trimethylamine n-oxide is associated with renal function in patients with heart failure with preserved ejection fraction. BMC Cardiovasc Disord. 2020;20:394.
Google Scholar
Ramezani A, Raj DS. The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol. 2014;25:657–70.
Google Scholar
Organ CL, Otsuka H, Bhushan S, Wang Z, Bradley J, Trivedi R, et al. Choline diet and its gut microbe-derived metabolite, trimethylamine N-Oxide, exacerbate pressure overload-induced heart failure. Circ Heart Fail. 2016;9:e002314.
Google Scholar
Huc T, Drapala A, Gawrys M, Konop M, Bielinska K, Zaorska E, et al. Chronic, low-dose TMAO treatment reduces diastolic dysfunction and heart fibrosis in hypertensive rats. Am J Physiol Heart Circ Physiol. 2018;315:H1805–20.
Google Scholar
Zhou J, Yu S, Tan Y, Zhou P, Liu C, Sheng Z, et al. Trimethylamine N-oxide was not associated with 30-day left ventricular systolic dysfunction in patients with a first anterior ST-segment elevation myocardial infarction after primary revascularization: a sub-analysis from an optical coherence tomography registry. Front Cardiovasc Med. 2020;7:613684.
Google Scholar
Koay YC, Chen Y-C, Wali JA, Luk AWS, Li M, Doma H, et al. Plasma levels of trimethylamine-N-oxide can be increased with “healthy” and “unhealthy” diets and do not correlate with the extent of atherosclerosis but with plaque instability. Cardiovasc Res. 2021;117:435–49.
Google Scholar
